[Treatment of atopic dermatitis with oxatomide oral suspension (2.5 mg/ml) in infants]
Related Experiment Video
Updated: Oct 29, 2026
Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
Published on: February 23, 2024
1Divisione Pediatrica, Ospedali Riuniti, Bergamo.
Insights
Oxatomide, an antiallergic drug, effectively and safely treats atopic dermatitis in children under 2 years old. Both tested low-dosage regimens showed significant symptom reduction within 60 days.
Area of Science:
- Pediatric Dermatology
- Allergy and Immunology
- Clinical Pharmacology
Background:
- Atopic dermatitis is a common skin condition in infants.
- Effective and safe treatments for young children are crucial.
- Oxatomide is a known antiallergic medication.
Purpose of the Study:
- To evaluate the efficacy and safety of oxatomide in children under 2 years with atopic dermatitis.
- To compare two different low-dose administration schedules of oxatomide.
Main Methods:
- A 60-day trial involving 20 children under 2 years old.
- Administration of oxatomide oral suspension (2.5 mg/mL) at 1 mg/kg/day (single evening dose) or 0.5 mg/kg every 12 hours.
- Assessment of cutaneous symptoms and adverse events at regular intervals.
Main Results:
- Significant reduction in atopic dermatitis symptoms, including itching and crusting, after 15 days.
- Erythema and papulovesicles improved by day 30.
- Both dosage regimens were effective and safe, with a single evening dose showing slightly faster improvement.
Conclusions:
- Low-dose oxatomide is an effective and safe antiallergic treatment for infants with atopic dermatitis.
- The drug is well-tolerated in this sensitive pediatric population.
- Further research may explore optimal dosing strategies.
Background:
The aim of the present trial is to determine the efficacy and safety profile of oxatomide, a potent antiallergic drug, in children aged under 2 years, suffering from atopic dermatitis. A comparison between 2 different dosage schemes was scheduled.
Methods:
An oral suspension of oxatomide, in a neonatological formulation at a low dosage (2.5 mg/mL) was administered to 20 children in the following manner: 1 mg/kg/day in a single evening dose (9); 0.5 mg/kg every 12 hrs (11) for a period of 60 days. Cutaneous symptoms were assessed at the baseline, and after 15, 30 and 60 days. All adverse events were recorded in detail.
Results:
After 15 days, at both doses, oxatomide significantly reduced (p < 0.05 vs baseline) atopical symptoms: itching, crusting, lesions due to scratching and after 30 days erythema and papulovesicles. No statistically significant differences were observed in terms of efficacy between the two dosage schemes, although oxatomide in a single dose led to a slightly faster improvement. Oxatomide displayed an excellent therapeutic safety profile.
Conclusions:
The results show that oxatomide in a low-dosage formulation is a good antiallergic drug, effective and safe in a specific population which is extremely delicate, such as children under 2 years old.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:23Ophthalmic Drug Delivery Systems
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:25Dosage Regimen: Multiple Oral Dosage
01:28IV Infusion to Oral Dosing: Conversion Methods
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...